CA2728623A1 - Combination treatment of glaucoma - Google Patents

Combination treatment of glaucoma Download PDF

Info

Publication number
CA2728623A1
CA2728623A1 CA2728623A CA2728623A CA2728623A1 CA 2728623 A1 CA2728623 A1 CA 2728623A1 CA 2728623 A CA2728623 A CA 2728623A CA 2728623 A CA2728623 A CA 2728623A CA 2728623 A1 CA2728623 A1 CA 2728623A1
Authority
CA
Canada
Prior art keywords
punctum
latanoprost
delivery system
days
eye drop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2728623A
Other languages
English (en)
French (fr)
Inventor
Zuhal Butuner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelion Therapeutics Inc
Original Assignee
QLT Plug Delivery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QLT Plug Delivery Inc filed Critical QLT Plug Delivery Inc
Publication of CA2728623A1 publication Critical patent/CA2728623A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
CA2728623A 2008-06-24 2009-06-24 Combination treatment of glaucoma Abandoned CA2728623A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7528408P 2008-06-24 2008-06-24
US61/075,284 2008-06-24
PCT/US2009/048452 WO2010008883A1 (en) 2008-06-24 2009-06-24 Combination treatment of glaucoma

Publications (1)

Publication Number Publication Date
CA2728623A1 true CA2728623A1 (en) 2010-01-21

Family

ID=41431875

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2728623A Abandoned CA2728623A1 (en) 2008-06-24 2009-06-24 Combination treatment of glaucoma

Country Status (7)

Country Link
US (1) US20090318549A1 (https=)
EP (1) EP2303184A4 (https=)
JP (1) JP2011525388A (https=)
CN (1) CN102105118A (https=)
CA (1) CA2728623A1 (https=)
TW (1) TW201012469A (https=)
WO (1) WO2010008883A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
SG170816A1 (en) 2006-03-31 2011-05-30 Qlt Plug Delivery Inc Drug delivery methods, structures, and compositions for nasolacrimal system
US9011361B2 (en) 2007-09-07 2015-04-21 Mati Therapeutics Inc. Lacrimal implant detection
CA2722971C (en) 2008-05-09 2019-05-07 Qlt Plug Delivery, Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
US8591484B2 (en) 2010-09-15 2013-11-26 AlphaMed, Inc. Lacrimal punctum measurement and occlusion
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP5989780B2 (ja) 2011-09-14 2016-09-07 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 眼挿入装置および方法
RU2652063C2 (ru) 2012-10-26 2018-04-24 Форсайт Вижн5, Инк. Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
CA2898644A1 (en) * 2013-01-24 2014-07-31 Rigel Pharmaceuticals, Inc. Composition for ophthalmic administration
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9424722B2 (en) * 2014-05-14 2016-08-23 Unlimited Liability, LLC Smart memory material lock devices
JP6555758B2 (ja) * 2014-09-22 2019-08-07 株式会社カネカ 内視鏡用注射器具
CN107645951B (zh) 2014-11-25 2021-05-04 艾克思摩尔有限公司 用于递送一种或多种生物活性剂的组合物和方法
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11291847B2 (en) * 2015-06-16 2022-04-05 The Regents Of The University Of Colorado, A Body Corporate Systems and methods for preventing, diagnosing, and/or treating one or more medical conditions via neuromodulation
CN105879126A (zh) * 2016-03-24 2016-08-24 杭州亚慧生物科技有限公司 一种超润滑血清白蛋白泪点塞及其制备方法
JP2021530253A (ja) * 2018-03-29 2021-11-11 マティ セラピューティクス，インク． 眼科用徐放性製剤およびドライアイ症候群治療のための使用
CN109568138B (zh) * 2019-01-10 2021-06-25 新疆国际旅行卫生保健中心 药片分割装置
US11207267B2 (en) 2019-10-02 2021-12-28 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US12447045B2 (en) 2019-10-02 2025-10-21 Segal Innovations LLC Bio-adhesive dissolving compounds and device
CA3209420A1 (en) 2021-02-24 2022-09-01 Peter Jarrett Intracanalicular depot inserter device

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
DK0637323T3 (da) * 1992-04-24 1999-05-25 Polymer Technology Group Inc Copolymerer og ikke-porøs, semipermeabel membran deraf og dens anvendelse til permeering af molekyler med et forudbestemt m
US5589563A (en) * 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
DK1592408T3 (da) * 2003-01-24 2010-01-04 Psivida Inc Indretning med depotvirkning og fremgangsmåde til okulær indgivelse af adrenergt midler
CA2513443A1 (en) * 2003-02-26 2004-09-10 Medivas, Llc Bioactive stents and methods for use thereof
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20050232972A1 (en) * 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2007047744A2 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
SG170816A1 (en) * 2006-03-31 2011-05-30 Qlt Plug Delivery Inc Drug delivery methods, structures, and compositions for nasolacrimal system
AR063619A1 (es) * 2006-12-18 2009-02-04 Alcon Res Ltd Dispositivos y metodos para la administraicion de un farmaco oftalmico
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
DK2207529T3 (en) * 2007-09-07 2015-03-09 Mati Therapeutics Inc PHARMACEUTICAL cores for the sustained release of therapeutic agents
RU2482822C2 (ru) * 2007-09-07 2013-05-27 Клт Инк. Инструменты для вставления и извлечения лакримальных имплантатов
EP2865361B1 (en) * 2007-09-07 2019-05-22 Mati Therapeutics Inc. Lacrimal implants and related methods
KR20100136453A (ko) * 2008-02-18 2010-12-28 큐엘티 플러그 딜리버리, 인코포레이티드 누관 임플란트 및 이와 관련된 방법
CN104623741A (zh) * 2008-04-30 2015-05-20 马缇医疗股份有限公司 复合泪管植入物及相关方法
CA2722971C (en) * 2008-05-09 2019-05-07 Qlt Plug Delivery, Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension

Also Published As

Publication number Publication date
EP2303184A4 (en) 2013-06-19
EP2303184A1 (en) 2011-04-06
WO2010008883A1 (en) 2010-01-21
JP2011525388A (ja) 2011-09-22
CN102105118A (zh) 2011-06-22
TW201012469A (en) 2010-04-01
US20090318549A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
US20090318549A1 (en) Combination treatment of glaucoma
CA2722971C (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US10632012B2 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
EP2389221B1 (en) Sustained released delivery of one or more agents
US20100274224A1 (en) Lacrimal implant body including comforting agent
US20140025022A1 (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
CA2872338C (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
HK1156835A (zh) 青光眼的聯合治療
HK1158951A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
HK1162151B (en) Sustained released delivery of one or more agents

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140625